Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
12.040USD
+0.150+1.26%
Close 07-29 16:00（ET）Quotes delayed by 15 min
316.06MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of Benitec Biopharma Inc is 8.67, ranking 74 out of 384 in the Biotechnology & Medical Research industry. The average price target is 27.00, with a high of 32.00 and a low of 18.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
24.167
Target Price
+108.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Benitec Biopharma Inc
BNTC
7
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Benitec Biopharma Inc's price target?
Analysts forecast that Benitec Biopharma Inc's price target is USD 27.00, with the highest forecast at USD 32.00 and the lowest forecast at USD 18.00.
How have Benitec Biopharma IncBNTC's recent earnings per share performed?
The market expectation was USD -0.24, while Benitec Biopharma IncBNTC's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.28.
What is the analyst rating for Benitec Biopharma Inc?
Based on the ratings of Benitec Biopharma Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.